A Study of Galunisertib in Participants With Myelodysplastic Syndromes

NCT02008318 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

43

Enrollment

INDUSTRY

Sponsor class

Conditions

Myelodysplastic Syndromes

Interventions

DRUG: Galunisertib
DRUG: Placebo

Sponsor

Eli Lilly and Company